🧬 CancerGuard™ MCED — Provider Brief · Precision Health w PA Courtney

🧬 CancerGuard™ MCED — Provider Brief

We currently screen for 4 major cancers with guideline-backed tools. Yet ~70% of cancer deaths come from cancers without routine screening. That’s the gap MCED testing is trying to close.

CancerGuard is a multi-cancer early detection (MCED) blood test developed by the team behind Cologuard®. It analyzes circulating tumor DNA (ctDNA) plus protein biomarkers to detect cancer-associated signals across multiple organ systems.

🔍 What It Screens For

CancerGuard evaluates signals associated with 50+ cancer types and subtypes, including:

Lung
Pancreatic
Hepatobiliary
Gastric & esophageal
Ovarian
Renal
Bladder
Head & neck
Select hematologic malignancies

It is not intended to replace:

Mammography
Colonoscopy/FIT
Pap/HPV screening
LDCT lung screening in high-risk patients

And it does not position itself as a primary screening tool for breast or prostate cancer.

This is additive screening — not substitution. It has high specificity over all leading to minimal false positives. But negative results is not a rule out!

📊 Performance Characteristics (Development Data)

Here’s the part you actually care about:

Overall sensitivity: ~64% across cancers detected in development studies
Specificity: ~97%
Stage I–II detection: ~1/3 of detected cancers

Translation:

Sensitivity varies by tumor type and stage (as expected). Performance is stronger in higher-stage disease and certain solid tumors. Specificity is high, which matters when you’re deploying this in asymptomatic populations.

False positives are relatively low, but not negligible. This means workflow planning matters.

🧠 Clinical Positioning

Intended population:

Age 50–84
No active cancer within 3 years
Average risk or elevated concern patients
Used in conjunction with standard screening

Cost: ~ $689 (cash-pay; HSA/FSA eligible)

This is not currently a USPSTF-endorsed screening modality.

🏥 Practical Workflow Considerations

Let’s be honest. The value of any screening test is not just sensitivity — it’s system integration.

You need a plan for:

Pre-test counseling Can be given at tie of lab draw (add 15 minutes to the visit)
Positive signal protocol ( be sure patients receive comfort and care when getting results delivered and be prepared with the follow up plan)
Documentation & shared decision-making

If you don’t build the downstream pathway, you’ll create anxiety without clarity. We do not want that for our patients or providers. Positive results should have an action plan.

⚖️ Comparison: Traditional Screening vs MCED

Traditional screening:

Organ-specific
High sensitivity for that organ
Evidence-based mortality reduction
Narrow scope

CancerGuard:

Multi-organ coverage
Moderate sensitivity overall
High specificity
Early-stage detection potential
No long-term mortality data yet (modeling only)

🔬 The Bigger Question

Is this the future of oncology screening?

Possibly.

Circulating tumor DNA is biologically plausible. Tumors shed material early. Detection technology is improving rapidly. But we are still in the early adoption phase — not yet at guideline integration.

The real discussion for providers isn’t “Is this cool?”

It’s:

Does this meaningfully improve stage shift?
What’s the cost-effectiveness?
How do we manage downstream testing burden?
Are we prepared for incidental findings?

Bottom Line for Providers

CancerGuard expands screening coverage to cancers that currently have none.

It has:

Solid specificity
Moderate overall sensitivity
Early-stage detection potential
Modeled mortality benefit

It does not replace guideline-based screening and should be implemented with structured follow-up planning.

This is frontier screening — promising, but not magic.

And like all early detection tools, the real impact will depend less on the test itself… and more on how intelligently we integrate it into clinical systems.

If you’d like, we can next build:• A clinical decision pathway algorithm• A shared decision-making script• Or a revenue + workflow integration model for DPC/concierge practices

Poll : Do you plan on implementing this in your practice as a recommended screening in longevity research?

Yes: excellent early detection tool

No: I don't want to create fear screening

1 vote

0 comments